On March 10, 2021 Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that new positive pre-clinical data on TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors, will be presented in two e-posters during AACR (Free AACR Whitepaper) Annual Meeting 2021 (Press release, Theratechnologies, MAR 10, 2021, View Source [SID1234576397]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Title: TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several sortilin positive (SORT1+) cancers
Abstract Number: 1313
E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM

Presentation Title: Increasing potency of anticancer drugs through SORT1+ Technology: A new targeted approach for the treatment of ovarian and endometrial cancers
Abstract number: 1439
E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM